Results filed 29 October 2026 · Market cap ₹1,376 crore · PE 38.6
GrowthGuidance maintainedTranscript read
Revenue
+102.3%
on a year ago
EBITDA
+83.7%
on a year ago
Profit to shareholders
+43.5%
on a year ago
EBITDA margin
23.9%
+6.1 pts on last quarter
Anlon Healthcare reported Q2 FY27 consolidated revenue of INR 105.61 crores and EBITDA of INR 25.24 crores, driven by sequential margin recovery to 23.9% and the consolidation of Apiqo Organics and Bizotic Lifescience. The company maintained its FY27 revenue target of INR 380-400 crores and guided for INR 650-700 crores in FY28, supported by an ongoing 1,200 MTPA Rajkot greenfield expansion. However, aggressive expansion into biologics and surgical devices, coupled with negative operating cash flow of INR 7.94 crores in H1 FY27 and a planned INR 250 crore fund raise, warrant close monitoring.
Source: Anlon Healthcare Limited’s filing to NSE, 29 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss, or, for earnings per share, because the number of shares changed.
What stood out
Massive top-line surge driven primarily by consolidation of acquired entities rather than standalone core organic growthSourceIn H1 FY27, Anlon Healthcare standalone contributed 44.6% of consolidated revenue, while acquired entities Apiqo Organics and Bizotic Lifescience contributed 43.7% and 11.7% respectively (Transcript, page 4; Presentation, page 30).
Sequentially rebounding EBITDA margin following price renegotiations to offset raw material inflationSourceEBITDA margin recovered from 17.8% in Q1 FY27 to 23.9% in Q2 FY27 (+610 bps QoQ) as price revisions took effect (Transcript, page 5; Presentation, page 31).
Proposed significant fund raise of up to INR 250 crores and a term loan of INR 65-70 crores to finance massive diversification and capexSourcePunitkumar Rasadia stated: 'we have just finalized it up to INR250 crores. That is what we have intimated to exchange... mostly going to be used for the further capex' along with 'around INR65 crores to INR70 crores of the term loan' (Transcript, pages 12, 15).
Guidance
Metric
Guidance
Period
Consolidated RevenueSourceTranscript, page 6: 'we are expecting between INR380 crores to INR400 crores in FY27. And we are almost in line with that target.'
INR 380 crores to INR 400 crores
FY27
Consolidated RevenueSourceTranscript, pages 6, 14: 'we are expecting between INR650 crores to INR700 crores in FY28.'
INR 650 crores to INR 700 crores
FY28
EBITDA MarginSourceTranscript, pages 7, 12: 'at least reach up to 25%, 26% at least in the total financial full year results by FY27... sustainable EBITDA margin for all consolidation is between 23% to 25%'
25% to 26% for full year FY27; sustainable band 23% to 25% (or 25% to 27% long-term)
FY27 / FY28
Operating Cash FlowSourceTranscript, page 6: 'consistent with the commitment we made to deliver positive operating cash flow by end of FY27.'
Positive operating cash flow
By end of FY27
Revenue targets of INR 380-400 cr for FY27 maintained, with FY28 revenue guidance introduced at INR 650-700 cr.
Tailwinds
Price pass-through driving QoQ gross margin and EBITDA margin expansionSourceManagement successfully increased finished goods prices to pass on elevated raw material costs, driving EBITDA margin to 23.9% from 17.8% QoQ (Transcript, pages 5, 7, 8).
Scale benefits from inorganic consolidation of Apiqo and BizoticSourceConsolidated H1 FY27 revenue rose 125.9% YoY to INR 193.17 crores with Apiqo contributing 43.7% and Bizotic 11.7% (Transcript, page 4; Presentation, page 31).
High entry-barrier moats in key profen moleculesSourceCompany holds registrations in Japan (PMDA), China (NMPA), Brazil (ANVISA) for Loxoprofen and CEP from EDQM for Ketoprofen with backward-integrated KSMs (Transcript, pages 4-5; Presentation, page 22).
Headwinds
Raw material inflation remains elevated without normalizationSourcePunitkumar Rasadia noted: 'raw material prices are not normalized yet. It is almost at par with what is increased after that war situation in the March' (Transcript, page 8).
Persistently negative operating cash flow due to working capital commitmentsSourceConsolidated net cash used in operating activities in H1 FY27 was negative INR 7.94 crores (-INR 794.3 lacs), with working capital changes draining INR 48.47 crores (Presentation, pages 32, 33; Transcript, page 5).
Delay in commercialization timelines for CDMO pipelineSourceMolecule 1 commercial supply delayed by 1-2 months into late Q3/early Q4 FY27, and commercialization for molecules 2 & 3 pushed out to post-H1 FY28 (Transcript, page 7).
US Ketoprofen DMF filing put on holdSourceKetoprofen US filing is 'on hold because we are expecting the U.S. FDA trigger by one of our customers, which has not started yet' (Transcript, page 11).
New businesses and products
new business · Incorporated, planning novel molecules and facility set-up; injectable facility expansion already started at Anlon Medicos
capacity expansion · Under construction; first floor finishing by end-November 2026, equipment installation starting; public hearing scheduled in December
Rajkot Parent Greenfield API Capacity Expansion
Expected benefit
Adds ~1,200 MTPA via 8 new clean lines allowing 8 APIs to run simultaneously
Risks
Potential delay of 1-2 months due to public hearing or regulatory/statutory approvals
Timeline
Completion by Q1 FY28, revenue generation from Q2 FY28
Investment
INR 130 crores total capex (INR 15-20 crores spent so far, funded via INR 65-70 cr bank loan and internal accruals)
33% more shares than a year ago: growth funded partly by new capital
Revenue up over 60%: check for an acquisition or a weak year-ago quarter
Severe working capital drag leading to persistent negative operating cash flow (-INR 7.94 cr in H1 FY27)SourceConsolidated Cash Flow Statement shows working capital outflow of INR 48.47 crores leading to operating cash flow of -INR 794.3 lacs (Presentation, page 33).
Rapid corporate expansion into unrelated fields (biologics, surgical implants, fine chemicals) funded via heavy leverage and equity dilutionSourceProposed equity fund raise of up to INR 250 crores, bank term loan of INR 65-70 crores, alongside incorporation of surgical device and biologic entities (Transcript, pages 12, 14, 15).
Question raised by analyst regarding SEBI 80% audit coverage complianceSourceAnalyst pointed out that only parent numbers appeared auditor-reviewed while subsidiaries were management-furnished, covering only ~57% of revenue (Transcript, page 11).
How the call went
The call offered helpful transparency regarding capacity expansion progress and segment breakdown, but displayed noticeable defensiveness when questioned on subsidiary audit review coverage and working capital metrics.
Specific or vague
Management provided detailed operational guidance on capacities, timelines, and segment revenue breakdowns, but gave somewhat vague responses regarding CDMO financial impacts and audit scope questions.
Candour
Management was open about CDMO delays and raw material price pressures not cooling down, but brushed off auditor review concerns somewhat dismissively.
The hard questions
Analysts probed into auditor review scope on subsidiaries, elongation of receivables vs shortened payable cycles, delays in DMF filings, and CDMO commercial supply timelines.
What analysts pressed on
Auditor review coverage: subsidiary accounts being management-furnished rather than auditor-reviewed under SEBI thresholds.
Working capital dynamics: high receivable days (123 days) vs short payable days (40 days) consuming cash.
Execution and approval risks on Greenfield Rajkot expansion and public hearing in December.
Aggressive multi-vertical diversification into medical devices and biologics while core API/intermediates integrate.
Answers that sidestepped
When asked about SEBI 80% auditor review requirement on subsidiaries, MD asserted 'consolidated is also reviewed' without directly clarifying whether individual subsidiary financials underwent independent statutory review (Transcript, page 11).
Vague response regarding the contribution of CDMO value addition to revenue numbers (Transcript, pages 8-9).
Numbers against the story
Management highlights massive top-line expansion exceeding FY26 in H1 FY27 alone (+125.9% YoY), but the financial statements show that 55.4% of consolidated H1 revenue comes from newly consolidated acquired entities (Apiqo and Bizotic) rather than the parent alone. While management claims working capital has improved due to customer collections, trade receivables actually climbed to INR 142.75 crores from INR 103.68 crores in March 2026, and operating cash flow remains negative at -INR 7.94 crores for H1 FY27.
Figures: the company’s results filing with NSE, linked under the table.
Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.